Real-time Estimate
Cboe BZX
12:10:40 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
5.425
USD
|
+0.28%
|
|
+9.31%
|
+10.43%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6.115
|
70.13
|
70.76
|
95.35
|
150.6
|
170.4
|
-
|
-
|
Enterprise Value (EV)
1 |
6.115
|
70.13
|
70.76
|
95.35
|
150.6
|
170.4
|
170.4
|
170.4
|
P/E ratio
|
-0.62
x
|
-3.9
x
|
-3.37
x
|
-3.27
x
|
-5.89
x
|
-5.61
x
|
55.5
x
|
4.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.08
x
|
226
x
|
289
x
|
37.4
x
|
5.98
x
|
7.96
x
|
1.9
x
|
1.39
x
|
EV / Revenue
|
6.08
x
|
226
x
|
289
x
|
37.4
x
|
5.98
x
|
7.96
x
|
1.9
x
|
1.39
x
|
EV / EBITDA
|
-0.79
x
|
-
|
-3.38
x
|
-3.27
x
|
-6.61
x
|
-5.72
x
|
-3.68
x
|
-4.36
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-18.9
x
|
-3.87
x
|
-15.5
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-5.28%
|
-25.8%
|
-6.45%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,777
|
20,448
|
24,149
|
24,703
|
30,793
|
31,503
|
-
|
-
|
Reference price
2 |
1.280
|
3.430
|
2.930
|
3.860
|
4.890
|
5.410
|
5.410
|
5.410
|
Announcement Date
|
3/18/20
|
3/11/21
|
3/10/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.005
|
0.3102
|
0.2449
|
2.551
|
25.18
|
21.4
|
89.52
|
122.5
|
EBITDA
1 |
-7.734
|
-
|
-20.94
|
-29.16
|
-22.79
|
-29.8
|
-46.3
|
-39.1
|
EBIT
1 |
-7.734
|
-13.69
|
-20.94
|
-29.7
|
-23.86
|
-34.35
|
7.832
|
31.83
|
Operating Margin
|
-769.52%
|
-4,412.56%
|
-8,549.79%
|
-1,163.93%
|
-94.76%
|
-160.53%
|
8.75%
|
25.99%
|
Earnings before Tax (EBT)
1 |
-7.642
|
-13.66
|
-20.02
|
-29.02
|
-22.29
|
-33.38
|
8.415
|
32.57
|
Net income
1 |
-7.642
|
-13.66
|
-20.02
|
-29.02
|
-22.29
|
-33.38
|
8.415
|
32.57
|
Net margin
|
-760.36%
|
-4,401.94%
|
-8,175.79%
|
-1,137.37%
|
-88.52%
|
-155.99%
|
9.4%
|
26.6%
|
EPS
2 |
-2.060
|
-0.8800
|
-0.8700
|
-1.180
|
-0.8300
|
-0.9650
|
0.0975
|
1.343
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-9
|
-44
|
-11
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-42.06%
|
-49.15%
|
-8.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
3/11/21
|
3/10/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.2356
|
-
|
-
|
-
|
-
|
1.592
|
0.9599
|
2.987
|
3.917
|
6.186
|
12.09
|
9.7
|
4.407
|
4.723
|
9.703
|
EBITDA
1 |
-
|
-4.315
|
-6.38
|
-
|
-7.322
|
-6.478
|
-7.875
|
-7.955
|
-7.493
|
-
|
-0.7554
|
-3.6
|
-10.3
|
-10
|
-5.8
|
EBIT
1 |
-
|
-4.315
|
-6.38
|
-
|
-7.322
|
-6.478
|
-8.066
|
-8.185
|
-7.747
|
-6.865
|
-1.063
|
-3.807
|
-8.893
|
-9.634
|
-4.732
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-407%
|
-840.33%
|
-274.04%
|
-197.76%
|
-110.97%
|
-8.79%
|
-39.25%
|
-201.81%
|
-203.98%
|
-48.76%
|
Earnings before Tax (EBT)
1 |
-
|
-3.932
|
-6.191
|
-
|
-7.109
|
-6.371
|
-7.721
|
-7.768
|
-7.367
|
-6.391
|
-0.7621
|
-3.482
|
-8.936
|
-9.451
|
-4.78
|
Net income
1 |
-
|
-3.932
|
-6.191
|
-
|
-7.109
|
-6.371
|
-7.721
|
-7.768
|
-7.367
|
-6.391
|
-0.7621
|
-3.482
|
-8.936
|
-9.451
|
-4.78
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-400.3%
|
-804.35%
|
-260.1%
|
-188.04%
|
-103.31%
|
-6.3%
|
-35.9%
|
-202.79%
|
-200.1%
|
-49.26%
|
EPS
2 |
-
|
-0.1700
|
-0.2600
|
-0.3200
|
-0.2900
|
-0.2600
|
-0.3100
|
-0.3100
|
-0.2900
|
-0.2500
|
-0.0200
|
-0.1133
|
-0.2867
|
-0.2967
|
-0.1333
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
11/9/21
|
3/10/22
|
5/10/22
|
8/10/22
|
11/10/22
|
3/15/23
|
5/11/23
|
8/7/23
|
11/14/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-9
|
-44
|
-11
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
3.36
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
131.68%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
3/11/21
|
3/10/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
5.41
USD Average target price
21
USD Spread / Average Target +288.17% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.43% | 170M | | -2.72% | 103B | | +1.72% | 95.28B | | +1.46% | 22.15B | | -15.75% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -12.98% | 16.05B | | +4.54% | 13.68B | | +35.38% | 12.17B |
Bio Therapeutic Drugs
|